Shandong Sinobioway Biomedicine Stock Forum

Shandong Sinobioway Biomedicine's high P/S ratio and slower growth rate may pose a risk to its share price. Overvaluation and continuation of recent revenue trends could negatively impact the share price.

Despite the recent sell-off, long-term investors may see this as an opportunity given the company's 13% annual return over five years. It's suggested to check the fundamental data for signs of a long term growth trend.

Shandong Sinobioway Biomedicine's high P/S ratio indicates a potential risk of share price decrease. Investors might pay excessive premium if recent medium-term revenue trends persist. The expected business turnaround could lead to disappointment if the P/S ratio aligns more with recent growth rates.